Tags : Hoth Therapeutics


Hoth Therapeutics Signs a License Agreement with UMB and Isoprene

Shots:  Hoth Therapeutics to get exclusive rights to evaluate UMB’s retinamides (RAMBAs) with an option to license the product to develop & commercialize therapies in the fields of dermatology and oncology  The focus of the agreement is to develop UMB’s novel retinamide Retinoic acid metabolism blocking agents (RAMBAs) therapies for cancer and dermatological diseases UMB’s […]Read More